General Information of Drug (ID: DMNZQO9)

Drug Name
TOPOSTATIN Drug Info
Synonyms topostatin; CHEMBL505529
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44559995
TTD Drug ID
DMNZQO9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug(s) Targeting DNA topoisomerase I (TOP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [2]
Topotecan DMP6G8T Central nervous system neoplasm Approved [2]
B-Lactams DMR8YD6 Bacterial infection 1A00-1C4Z Approved [3]
Belotecan hydrocholoride DM3SRJZ Small-cell lung cancer 2C25.Y Approved [4]
Topetecan DMAE6LK Small-cell lung cancer 2C25.Y Approved [5]
Karenitecin DMCRGY4 Lung cancer 2C25.0 Phase 3 [6]
Camptothecin DM6CHNJ Solid tumour/cancer 2A00-2F9Z Phase 3 [7]
Exatecan DMCA7FN Solid tumour/cancer 2A00-2F9Z Phase 3 [8]
Edotecarin DM3ZL7D Gastric adenocarcinoma 2B72 Phase 3 [9]
Rubitecan DMDWU1S Human immunodeficiency virus infection 1C62 Phase 3 [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting DNA topoisomerase (TOP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Karenitecin DMCRGY4 Lung cancer 2C25.0 Phase 3 [11]
Icofungipen DMTXNZK Fungal infection 1F29-1F2F Phase 2 [12]
6-(3-Ethyl-phenylamino)-1H-pyrimidine-2,4-dione DMKUHN9 Discovery agent N.A. Investigative [13]
N*4*-Benzyl-6-chloro-pyrimidine-2,4-diamine DMNGSQK Discovery agent N.A. Investigative [14]
5-Bromo-6-p-tolylamino-1H-pyrimidine-2,4-dione DMTPRIW Discovery agent N.A. Investigative [14]
6-Benzylamino-1H-pyrimidine-2,4-dione DM8FUZL Discovery agent N.A. Investigative [14]
6-(3-Bromo-phenylamino)-1H-pyrimidine-2,4-dione DMMFWYX Discovery agent N.A. Investigative [13]
6-(Indan-5-ylamino)-1H-pyrimidine-2,4-dione DMSH107 Discovery agent N.A. Investigative [13]
6-Benzylamino-5-bromo-1H-pyrimidine-2,4-dione DMGJYWF Discovery agent N.A. Investigative [14]
2-Amino-6-(indan-5-ylamino)-3H-pyrimidin-4-one DMECHD0 Discovery agent N.A. Investigative [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting DNA topoisomerase II (TOP2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [2]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [15]
Teniposide DMLW57T Acute lymphoblastic leukaemia 2A85 Approved [2]
Mitoxantrone DMM39BF Acute myelogenous leukaemia 2A41 Approved [16]
Idarubicin DMM0XGL Acute myelogenous leukaemia 2A41 Approved [2]
Epirubicin DMPDW6T Solid tumour/cancer 2A00-2F9Z Approved [2]
Lomefloxacin DMVRH9C Bacterial infection 1A00-1C4Z Approved [17]
Dexrazoxane DMD7X1O Breast cancer 2C60-2C65 Approved [2]
Podofilox DMT2EJP Condyloma 1A95 Approved [18]
Enoxacin DMYTE6L Acute gonococcal cervicitis Approved [19]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase (TOP) TT2GPK3 NOUNIPROTAC Inhibitor [1]
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Inhibitor [1]
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Inhibitor [1]

References

1 Isoaurostatin, a novel topoisomerase inhibitor produced by Thermomonospora alba. J Nat Prod. 2001 Feb;64(2):204-7.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J. 2002 Sep 1;366(Pt 2):653-61.
4 Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43.
5 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
6 Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol.2000 Mar;57(3):453-9.
7 Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802.
8 Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001 Dec;7(12):3963-70.
9 Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.
10 Rubitecan. Expert Opin Investig Drugs. 2006 Jan;15(1):71-9.
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12 Crystallization and preliminary X-ray analysis of anti-cancer agent 3-(9-acridinylamino)-5-(hydroxymethyl)aniline complexed with the DNA hexamer d(CGTACG)2. Biochim Biophys Acta. 2003 Jan 3;1625(1):27-9.
13 Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8.
14 Inhibitors of Bacillus subtilis DNA polymerase III. Influence of modifications in the pyrimidine ring of anilino- and (benzylamino)pyrimidines. J Med Chem. 1986 May;29(5):676-81.
15 Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
16 Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
17 Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
18 Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
19 Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.